The recall covers 7,107 bottles of duloxetine, the FDA said. The bottles include 500 delayed-release 20mg capsules. The lot number is 220128, with an expiration date of 12/2024. The recall of the Duloxetine Delayed-Release Capsules, produced by Towa Pharmaceutical Europe, was initiated on October 10 and has been given the second highest risk classification by the FDA. CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the proposed interim limit. What is the Reason for Recall? Information describing how the product is defective. Product Quantity: 7,188/ 500 count bottles Product Quantity The amount of product subject to recall. Voluntary Mandated Earlier this month the FDA announced a recall of 7,107 bottles of Duloxetine Delayed-Release Capsules because of an elevated level of a cancer-causing chemical known as N-nitroso-duloxetine. What Duloxetine Users Should Do in the Wake of the Recall Per Mayo Clinic , Duloxetine, which is known by brand names Cymbalta, Drizalma Sprinkle, and Irenka, is used to treat depression and anxiety. May 7, 2024 · Clinical Team. On May 4, 2024, the U.S. Food and Drug Administration (FDA) reported that Breckenridge Pharmaceutical, Inc., (Breckenridge) issued a retail level recall of duloxetine delayed-release capsules. This recall was initiated due to the presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine Duloxetine (marketed as Cymbalta) is included in the class of drugs called selective serotonin/norepinephrine reuptake inhibitors (SNRIs). This class of drugs is used to treat depression, anxiety To date, Breckenridge is not aware of reports of adverse events that have been assessed to be related to this recall. This recall is being initiated with the knowledge of the Food and Drug Administration and should be carried out to the Retail Level. Product. Duloxetine Delayed -Release Capsules USP, 60 mg. Duloxetine Delayed-Release Capsules Please

be advised that Breckenridge Pharmaceutical, Inc. (Breckenridge) is performing a Retail Level Class II Recall of Duloxetine Delayed-Release Capsules, USP, 20mg, 30mg, 60mg, manufactured by Towa Pharmaceutical Europe, S.L. The lots listed below are being recalled due to presence of Nitrosamine Drug Substance Related Impurity (NDSRJ), N TRACK DOCKET: No. 2:24-cv-06514. Breckenridge Pharmaceutical Inc. knowingly sold millions of tablets of duloxetine, a generic form of anti-anxiety medication Cymbalta, though it was contaminated with a carcinogenic, a proposed class action alleges. The company announced a voluntary recall at the end of April due to elevated levels of The US Food and Drug Administration has recalled thousands of bottles of Duloxetine antidepressant, saying it contained high levels of a cancer-causing chemical. The federal agency has reportedly Duloxetine is used to treat depression and anxiety. It is also used for pain caused by nerve damage associated with diabetes (diabetic peripheral neuropathy). Duloxetine is also used to treat fibromyalgia (muscle pain and stiffness) and chronic (long-lasting) pain that is related to muscles and bones. Duloxetine belongs to a group of medicines NEW YORK (PIX11) - The Federal Drug Administration issued a recall on Tuesday for a common medicine for depression. Over 7,000 bottles of Duloxetine were recalled due to the elevated presence of A recall is a voluntary action taken by a company to remove a defective drug product from the market or warn patients and consumers about a potential risk. The list below includes voluntary drug The Duloxetine recall has now significantly expanded. In separate actions, the FDA announced a recall of over 18 million more pills associated with Breckenridge's drug application. Drug Recalls: What You Need to Know. September 16, 2024. Update on Glenmark's Recall of Potassium Chloride Extended-Release Capsules. September 3, 2024. The Most people experience side effects with duloxetine and

one in six people stops taking the drug because of them. Severe skin reactions and urinary retention have also been reported with duloxetine. An increased risk of suicidal thoughts, especially in young adults under the age of 24 (similar to other antidepressants). Duloxetine is a medication used to manage major depressive disorder (MDD), generalized anxiety disorder (GAD), fibromyalgia, diabetic peripheral neuropathy, and chronic musculoskeletal pain. Off-label uses for duloxetine include chemotherapy-induced peripheral neuropathy and stress urinary incontinence. It is in the Serotonin and norepinephrine reuptake inhibitors (SNRIs) class of medications The last Recall Enforcement Report for Duloxetine Delayed-release with NDC 60429-166 was initiated on 05-13-2024 as a Class II recall due to cgmp deviations: presence of nitrosamine drug substance related impurity (ndsri), n-nitroso-duloxetine, above the proposed interim limit. The latest recall number for this product is D-0568-2024 and the The last Recall Enforcement Report for Duloxetine Delayed-release with NDC 51991-748 was initiated on 05-17-2024 as a Class II recall and it is currently. Search. Home; Lookup Tools. The information in this website is intended for healthcare providers and consumers in the United States. The absence of a warning or notice for a given drug or Duloxetine may cause problems in newborns following delivery if it is taken during the last months of pregnancy. if you are having surgery, including dental surgery, tell the doctor or dentist that you are taking duloxetine. you should know that duloxetine may make you drowsy, dizzy, or may affect your judgment, thinking or coordination.

デュロキセチン（Duloxetine）は、セロトニン・ノルアドレナリン再取り込み阻害薬（SNRI）と呼ばれる抗うつ薬の一つである。日本では2010年からサインバルタの商品名で知られる。薬機法における劇薬である。 The October 10 recall is due to the presence of N-nitroso-duloxetine, a chemical that is toxic if swallowed and is suspected of causing cancer, according to the National Library of Medicine. Earlier this month the FDA announced a recall of 7,107 bottles of Duloxetine Delayed-Release Capsules because of an elevated level of a cancer-causing chemical known as N-nitroso-duloxetine. The recall, which affects the drug’s delayed-release capsules, came after Duloxetine was found to contain more than the acceptable limit of N-nitroso-duloxetine.  What Duloxetine Users Should Do in the Wake of the Recall. The FDA announced that 7,107 bottles of Duloxetine Delayed-Release Capsules - sold under the brand name Cymbalta - have been recalled due to containing a potentially cancer-causing chemical. Injured persons who want to know if they received any of these batch numbers should contact their pharmacy, or their prescriber to discuss the use of duloxetine. The FDA is assigning the second-highest risk level to the recall of Duloxetine Delayed-Release Capsules, produced by Towa Pharmaceutical Europe, according to agency records and reported by SILive.com sister site NJ.com. The FDA is assigning the drug duloxetine delayed-release capsules to the second-highest risk level after drug distribution company, Breckenridge Pharmaceutical Inc ., voluntarily issued the recall earlier this month . Duloxetine belongs to a group of medicines called

Selective Serotonin and Norepinephrine Reuptake Inhibitors (SSNRIs). Cymbalta (duloxetine) is a prescription antidepressant used to treat depression, anxiety, and some other conditions. The duloxetine (Cymbalta) dosage should be gradually reduced when therapy is discontinued to prevent symptoms of withdrawal. Health product recall. PMS-Duloxetine 60 mg: Exceeds acceptable interim intake limit for N-nitroso-duloxetine (NDLX). • you should know that duloxetine may cause angle-closure glaucoma (a condition where the fluid is suddenly blocked and unable to flow out of the eye causing a quick, severe increase in eye pressure which may lead to a loss of vision). Duloxetine(Cymbalta) generic Duloxetine belongs to a class of drugs known as serotonin-norepinephrine reuptake inhibitors. Duloxetine should not be taken with or within 2 weeks of taking monoamine oxidase inhibitors (MAOIs).